HDAC9 and adrenal cortex carcinoma: Which contributes to new targeted gene therapies, including the use of BET and HDAC inhibitors.[24] Further studies on the specific roles of these chromosomal translocations may provide new insights into the oncogenic driver and potential therapeutic target of vulvar ACC, thus promoting the personalized, precise treatment of this disease.